PNC Financial Services Group
PRVB

PNC Financial Services Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

PNC Financial Services Group’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,375
Closed -$33.1K – 4892
2023
Q1 		$33.1K Sell
1,375
-1,250
-48% -$15.7K ﹤0.01% 3209
2022
Q4 		$27.7K Buy
2,625
+2,000
+320% +$16.1K ﹤0.01% 3306
2022
Q3 		$3K Hold
625
– – ﹤0.01% 4131
2022
Q2 		$3K Hold
625
– – ﹤0.01% 4150
2022
Q1 		$5K Sell
625
-70
-10% -$419 ﹤0.01% 4024
2021
Q4 		$4K Sell
695
-2,000
-74% -$12.7K ﹤0.01% 4049
2021
Q3 		$17K Sell
2,695
-189
-7% -$1.22K ﹤0.01% 3583
2021
Q2 		$24K Buy
2,884
+659
+30% +$5.32K ﹤0.01% 3400
2021
Q1 		$23K Hold
2,225
– – ﹤0.01% 3360
2020
Q4 		$38K Hold
2,225
– – ﹤0.01% 3062
2020
Q3 		$29K Hold
2,225
– – ﹤0.01% 3047
2020
Q2 		$31K Buy
2,225
+2,025
+1,013% +$25.6K ﹤0.01% 3007
2020
Q1 		$2K Buy
+200
New +$2.58K ﹤0.01% 3769

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

PNC Financial Services Group's PRVB Position: Q2 2023 in Review

PNC Financial Services Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,375 shares — an estimated $33.1K sold.

PNC Financial Services Group first reported a position in PRVB in Q1 2020 and held it in 13 quarters. The position peaked at $38K in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • PNC Financial Services Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 1,375 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $33.1K.
  • PNC Financial Services Group first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 13 quarters.
  • PNC Financial Services Group's Provention Bio, Inc. Common Stock position peaked at $38K in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on PNC Financial Services Group's 13F filing for Q2 2023, filed 11 Aug 2023.